(Q38203844)

31 August 2017

Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection (English)

1 reference

31 August 2017

1 reference

Danielle A Osterholzer

series ordinal

1

1 reference

PubMed ID

24723281

31 August 2017

Mitchell Goldman

series ordinal

2

1 reference

PubMed ID

24723281

31 August 2017

language of work or name

English

0 references

publication date

9 April 2014

1 reference

Clinical Infectious Diseases

31 August 2017

1 reference

31 August 2017

59

1 reference

31 August 2017

2

1 reference

31 August 2017

265-271

1 reference

Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States

31 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU221

21 January 2018

Identifiers

DOI

10.1093/CID/CIU221

1 reference

31 August 2017

1 reference

PubMed ID

24723281